| First Author | Badodi S | Year | 2021 |
| Journal | Nat Commun | Volume | 12 |
| Issue | 1 | Pages | 2148 |
| PubMed ID | 33846320 | Mgi Jnum | J:335054 |
| Mgi Id | MGI:6713672 | Doi | 10.1038/s41467-021-22379-7 |
| Citation | Badodi S, et al. (2021) Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nat Commun 12(1):2148 |
| abstractText | Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1(High);CHD7(Low) signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1(High);CHD7(Low) xenograft model. |
